KDR and neoplasm: The clinical trials, like KEYNOTE-426 and IMbrave 150, found that full or high dose anti-VEGFR2 therapy plus PD-1 inhibitor significantly longer survival in some tumor types, which implied that high dose anti-VEGFR2 therapy closely related to the inhibitory immune microenvironment (48, 49).